Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
or

Solid Biosciences Inc (SLDB)

Solid Biosciences Inc (SLDB)
2.55 x 3 2.76 x 3
Post-market by (Cboe BZX)
2.67 -0.07 (-2.55%) 04/10/25 [NASDAQ]
2.55 x 3 2.76 x 3
Post-market 2.67 unch (unch) 16:02 ET
Quote Overview for Thu, Apr 10th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
2.58
Day High
2.79
Open 2.79
Previous Close 2.74 2.74
Volume 793,400 793,400
Avg Vol 1,195,785 1,195,785
Stochastic %K 7.28% 7.28%
Weighted Alpha -84.36 -84.36
5-Day Change -0.73 (-21.59%) -0.73 (-21.59%)
52-Week Range 2.47 - 11.28 2.47 - 11.28
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 212,331
  • Shares Outstanding, K 77,493
  • Annual Sales, $ 0 K
  • Annual Income, $ -124,700 K
  • EBIT $ -130 M
  • EBITDA $ -131 M
  • 60-Month Beta 2.07
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.78

Options Overview Details

View History
  • Implied Volatility 656.51% ( -105.79%)
  • Historical Volatility 96.64%
  • IV Percentile 99%
  • IV Rank 85.79%
  • IV High 762.29% on 04/09/25
  • IV Low 17.80% on 07/08/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 2
  • Volume Avg (30-Day) 378
  • Put/Call OI Ratio 0.52
  • Today's Open Interest 4,585
  • Open Int (30-Day) 6,691

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 12 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -0.53
  • Number of Estimates 7
  • High Estimate -0.31
  • Low Estimate -0.77
  • Prior Year -0.64
  • Growth Rate Est. (year over year) +17.19%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.47 +7.88%
on 04/09/25
Period Open: 5.09
5.85 -54.36%
on 03/12/25
-2.42 (-47.54%)
since 03/10/25
3-Month
2.47 +7.88%
on 04/09/25
Period Open: 3.68
7.20 -62.92%
on 02/18/25
-1.01 (-27.45%)
since 01/10/25
52-Week
2.47 +7.88%
on 04/09/25
Period Open: 10.83
11.28 -76.33%
on 04/11/24
-8.16 (-75.35%)
since 04/10/24

Most Recent Stories

More News
Can Solid Biosciences Challenge Sarepta in the DMD Market?

Solid Biosciences' Duchenne muscular dystrophy (DMD) drug could provide superior outcomes compared to an already approved medication projected to make billions.

SLDB : 2.67 (-2.55%)
SRPT : 50.31 (-9.60%)
Solid Biosciences to Participate at Upcoming Investor Conferences

SLDB : 2.67 (-2.55%)
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SLDB : 2.67 (-2.55%)
Climb Bio Appoints Seasoned Biotech Leaders to Board of Directors

SLDB : 2.67 (-2.55%)
CLYM : 1.1600 (-4.13%)
IMU.AX : 0.024 (unch)
LENZ : 18.54 (-9.21%)
ABOS : 1.0200 (-3.77%)
VERV : 3.05 (-10.56%)
Solid Biosciences to Present at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

SLDB : 2.67 (-2.55%)
Solid Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

SLDB : 2.67 (-2.55%)
Solid Biosciences to Participate at Upcoming Investor Conferences

SLDB : 2.67 (-2.55%)
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SLDB : 2.67 (-2.55%)
Top 5 Biotech Stocks That Saw Biggest Retail Following Jump Last Week

Investors on Stocktwits flocked to these five biotech stocks last week, ending Feb. 21, 2025, driven by buyout buzz, bullish analyst calls, and promising clinical developments.

SLDB : 2.67 (-2.55%)
SLRN : 2.15 (-1.15%)
ESLA : 0.9100 (+2.48%)
CADL : 4.77 (-6.29%)
ADTX : 2.88 (-4.00%)
Solid Biosciences Soars 32% on Trial Data: 189% Upside from Here?

Solid Biosciences just saw a 32% move to the upside after its trial results impressed. What's next for this firm that analysts still see massive potential in?

SLDB : 2.67 (-2.55%)
SRPT : 50.31 (-9.60%)
Solid Biosciences' Retail Following Swells Amid Stock's Best Run In A Year — What's Behind The Move?

Early-stage data from the company's gene therapy candidate SGT-003 for Duchenne muscular dystrophy (DMD) showed encouraging results.

SLDB : 2.67 (-2.55%)
VXF : 158.20 (-4.54%)
IBB : 113.14 (-4.63%)
VTI : 257.43 (-4.12%)
IWM : 181.71 (-4.20%)
Solid Biosciences Announces Pricing of Underwritten Offering

SLDB : 2.67 (-2.55%)
Solid Biosciences Reports Positive Initial Clinical Data from Next-Generation Duchenne Gene Therapy Candidate SGT-003

SLDB : 2.67 (-2.55%)
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SLDB : 2.67 (-2.55%)
Solid Biosciences Receives FDA Fast Track Designation for SGT-212 Dual Route of Administration Gene Therapy for Friedreich’s Ataxia

SLDB : 2.67 (-2.55%)
Solid Biosciences Outlines Key Priorities for Advancing Diversified Neuromuscular and Cardiac Development Pipeline and Establishing Leadership in Precision Genetic Medicines

SLDB : 2.67 (-2.55%)
Solid Biosciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference

SLDB : 2.67 (-2.55%)
Solid Biosciences Announces FDA IND Clearance for First-In-Industry Dual Route of Administration Gene Therapy to Treat Both Neurologic and Cardiac Manifestations of Friedreich’s Ataxia

SLDB : 2.67 (-2.55%)
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SLDB : 2.67 (-2.55%)
Solid Biosciences Added to the Nasdaq Biotechnology Index

SLDB : 2.67 (-2.55%)
Insider Sale: President and CEO of $SLDB (SLDB) Sells 11,114 Shares

Alexander Cumbo, the President and CEO of $SLDB ($SLDB), sold 11,114 shares of the company on 12-03-2024. We received data on the trade from a recent SEC filing. This was a sale of approximately 22.4%...

SLDB : 2.67 (-2.55%)
Insider Sale: Chief Technology Officer of $SLDB (SLDB) Sells 2,777 Shares

Paul Herzich, the Chief Technology Officer of $SLDB ($SLDB), sold 2,777 shares of the company on 12-03-2024. We received data on the trade from a recent SEC filing. This was a sale of approximately 18.6%...

SLDB : 2.67 (-2.55%)
Solid Biosciences Announces Collaboration with Mayo Clinic to Accelerate Gene Therapy Innovation and Advance Development of Cardiac Gene Therapies

SLDB : 2.67 (-2.55%)
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SLDB : 2.67 (-2.55%)
Solid Biosciences to Participate at Upcoming Investor Conferences

SLDB : 2.67 (-2.55%)
Solid Biosciences to Present at the Jefferies London Healthcare Conference

SLDB : 2.67 (-2.55%)
Solid Biosciences Reports Third Quarter 2024 Financial Results and Provides Business Updates

SLDB : 2.67 (-2.55%)
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SLDB : 2.67 (-2.55%)
Solid Biosciences to Participate at the Truist Securities BioPharma Symposium

SLDB : 2.67 (-2.55%)
Are Gene Therapy Stocks The Market's Next Big Winners?

Biotechs Sarepta and BioMarin are among companies advancing cutting-edge gene therapies, although those treatments can come with a $2 million or more price.

SRPT : 50.31 (-9.60%)
BMRN : 56.32 (-5.23%)
BIIB : 113.38 (-5.90%)
CRSP : 34.26 (-1.81%)
EDIT : 1.1100 (-3.48%)
NTLA : 6.77 (-4.38%)
NVS : 103.40 (-0.43%)
ORTX : 16.70 (+0.30%)
REGN : 546.39 (-5.26%)
SLDB : 2.67 (-2.55%)
BLUE : 4.67 (-3.71%)

Business Summary

Solid Biosciences LLC is a life science company. It focuses on developing therapies for Duchenne muscular dystrophy. The company is engaged in developing gene therapies, disease modifying therapies and assistive devices, all targeting the various facets of the DMD. Its product candidate includes SGT-001,...

See More

Key Turning Points

3rd Resistance Point 2.99
2nd Resistance Point 2.89
1st Resistance Point 2.78
Last Price 2.67
1st Support Level 2.57
2nd Support Level 2.47
3rd Support Level 2.36

See More

52-Week High 11.28
Fibonacci 61.8% 7.92
Fibonacci 50% 6.88
Fibonacci 38.2% 5.84
Last Price 2.67
52-Week Low 2.47

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar